title: Arsenic trioxide-based therapy is suitable for patients with psoriasis-associated acute promyelocytic leukemia - A retrospective clinical study.
abstract: OBJECTIVE
  Many patients with psoriasis have developed acute promyelocytic leukemia (APL) whereas few reports on psoriasis-associated APL were found in the published literature. This study was aimed to study the etiology, clinical characteristics, and prognosis of psoriasis-associated APL and to map a suitable treatment regime for this condition.
  
  
  METHODS
  This study retrospectively analyzed the clinical data of 17 patients with psoriasis-associated APL diagnosed and treated in our hospital in the past decade.
  
  
  RESULTS
  The 17 patients accounted for 8.3% of the total patients diagnosed with de novo APL during the same period in our hospital. Their clinical characteristics of APL were similar to those of general APL. Four patients had a definite history of taking bimolane. All patients received arsenic trioxide (ATO)-based remission induction and postremission treatment. After induction, 15 patients (88%) achieved hematologic complete remission. With a median follow-up of 27 months, the 3-year estimates of overall survival were 77.2% ± 12.4% and the 3-year estimates of event-free survival were 70.6% ± 13.5%. In addition, the ATO-based remission induction and postremission treatment significantly improved psoriasis symptoms in 83 and 85.7% of patients, respectively. Through the final follow-up, no chronic arsenicosis or secondary malignancy was observed.
  
  
  CONCLUSIONS
  Psoriasis patients are at high risk for APL. The increased risk is most likely associated with the genetic background and bimolane treatment. The ATO-based therapy is especially suitable for patients with psoriasis-associated APL. Our study also brings a new treatment option for psoriasis.
authors.affiliation: a Department of Hematology , The First Affiliated Hospital, Harbin Medical University , China.
authors.forename: Fei
authors.initials: F
authors.lastname: Ge
authors.affiliation: b Central Laboratory , The First Affiliated Hospital, Harbin Medical University , China.
authors.forename: Yingmei
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: b Central Laboratory , The First Affiliated Hospital, Harbin Medical University , China.
authors.forename: Fenglin
authors.initials: F
authors.lastname: Cao
authors.affiliation: a Department of Hematology , The First Affiliated Hospital, Harbin Medical University , China.
authors.forename: Jinmei
authors.initials: J
authors.lastname: Li
authors.affiliation: a Department of Hematology , The First Affiliated Hospital, Harbin Medical University , China.
authors.forename: Jinxiao
authors.initials: J
authors.lastname: Hou
authors.affiliation: a Department of Hematology , The First Affiliated Hospital, Harbin Medical University , China.|c Department of Neonatology , The First Affiliated Hospital, Harbin Medical University , China.
authors.forename: Ping
authors.initials: P
authors.lastname: Wang
authors.affiliation: a Department of Hematology , The First Affiliated Hospital, Harbin Medical University , China.
authors.forename: Haitao
authors.initials: H
authors.lastname: Li
authors.affiliation: a Department of Hematology , The First Affiliated Hospital, Harbin Medical University , China.
authors.forename: Mengyuan
authors.initials: M
authors.lastname: Xu
authors.affiliation: a Department of Hematology , The First Affiliated Hospital, Harbin Medical University , China.
authors.forename: Shuchuan
authors.initials: S
authors.lastname: Liu
authors.affiliation: a Department of Hematology , The First Affiliated Hospital, Harbin Medical University , China.
authors.forename: Limin
authors.initials: L
authors.lastname: Li
authors.affiliation: a Department of Hematology , The First Affiliated Hospital, Harbin Medical University , China.
authors.forename: Xiaoxia
authors.initials: X
authors.lastname: Li
authors.affiliation: a Department of Hematology , The First Affiliated Hospital, Harbin Medical University , China.
authors.forename: Shuye
authors.initials: S
authors.lastname: Wang
authors.affiliation: a Department of Hematology , The First Affiliated Hospital, Harbin Medical University , China.
authors.forename: Chengfang
authors.initials: C
authors.lastname: Lv
authors.affiliation: a Department of Hematology , The First Affiliated Hospital, Harbin Medical University , China.
authors.forename: Yanhua
authors.initials: Y
authors.lastname: Su
authors.affiliation: a Department of Hematology , The First Affiliated Hospital, Harbin Medical University , China.|b Central Laboratory , The First Affiliated Hospital, Harbin Medical University , China.
authors.forename: Jin
authors.initials: J
authors.lastname: Zhou
mesh_terms: D000293:Adolescent; D000328:Adult; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage* / Q000009:adverse effects; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D010087:Oxides / Q000008:administration & dosage* / Q000009:adverse effects; D011565:Psoriasis / Q000150:complications* / Q000188:drug therapy* / Q000401:mortality; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D001152:Arsenicals; D010087:Oxides; D000077237:Arsenic Trioxide
keywords: Acute promyelocytic leukemia; Arsenic trioxide; Bimolane; Psoriasis